Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company founded in 2015 in the United States, focusing on the development of novel, first-in-class, small-molecule therapies for immune-mediated and oncologic disorders. The company's slogan "Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders" reflects their commitment to leveraging cutting-edge science and innovation to transform patient outcomes. Their approach involves harnessing master regulators of cellular function and inhibiting multiple drivers of disease via a single target, with the potential to create significant clinical impact in challenging-to-treat conditions. The company recently received a substantial $12.16M Post-IPO Equity investment on 03 October 2022, with Morningside Venture Investments participating as the lead investor. Kezar's ambitious therapeutic platforms have the potential to address a wide array of indications, offering hope for patients in need across various conditions within the Health Care, Health and Wellness, and Life Sciences sectors.